ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation

Completed

Conditions: Acute Myeloid Leukemia (AML)

First Posted Date: 2020-02-05

Last Posted Date: 2024-11-07

Lead Sponsor: AbbVie

Target Recruit Count: 51

Registration Number: NCT04253314

Locations: 🇷🇺
Hematology department State budgetary health care institution Volgograd region /ID# 229813, Volgograd, Volgogradskaya Oblast, Russian Federation
🇷🇺
Regional Clinical Hospital of Irkutsk /ID# 218570, Irkutsk, Russian Federation
🇷🇺
Clinical Medico-Sanitary Unit #1 /ID# 222502, Perm, Russian Federation

and more 7 locations

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

Phase 1

Completed

Conditions: Human Immunodeficiency Virus (HIV)
HIV-1
HIV Infection

Interventions: Drug: Placebo
Drug: ABBV-181

First Posted Date: 2020-01-10

Last Posted Date: 2023-03-09

Lead Sponsor: AbbVie

Target Recruit Count: 41

Registration Number: NCT04223804

Locations: 🇺🇸
Franco Felizarta, Md /Id# 215721, Bakersfield, California, United States
🇺🇸
Ruane Clinical Research Group /ID# 224866, Los Angeles, California, United States
🇺🇸
Quest Clinical Research /ID# 215796, San Francisco, California, United States

and more 20 locations

A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus

Completed

Conditions: Hepatitis C Virus (HCV)

First Posted Date: 2019-12-30

Last Posted Date: 2024-10-29

Lead Sponsor: AbbVie

Target Recruit Count: 50

Registration Number: NCT04214028

Locations: 🇯🇵
Kariya Toyota General Hospital /ID# 239046, Kariya-shi, Aichi, Japan
🇯🇵
Nagoya City University Hospital /ID# 238745, Nagoya shi, Aichi, Japan
🇯🇵
Meijo Hospital /ID# 250955, Nagoya-shi, Aichi, Japan

and more 51 locations

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Phase 3

Completed

Conditions: Epithelial Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions: Drug: Paclitaxel
Drug: Mirvetuximab Soravtansine
Drug: Topotecan
Drug: Pegylated liposomal doxorubicin

First Posted Date: 2019-12-24

Last Posted Date: 2025-01-07

Lead Sponsor: AbbVie

Target Recruit Count: 453

Registration Number: NCT04209855

Locations: 🇺🇸
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

and more 210 locations

A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)

Completed

Conditions: Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Leukemia (SLL)
Cancer

First Posted Date: 2019-12-13

Last Posted Date: 2023-10-19

Lead Sponsor: AbbVie

Target Recruit Count: 4

Registration Number: NCT04198415

Locations: 🇯🇵
Nagoya City University Hospital /ID# 240820, Nagoya shi, Aichi, Japan
🇯🇵
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 239524, Nagoya-shi, Aichi, Japan
🇯🇵
Aso Iizuka Hospital /ID# 221140, Iizuka-shi, Fukuoka, Japan

and more 99 locations

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 1

Completed

Conditions: Advanced Solid Tumors Cancer

Interventions: Drug: ABBV-368
Drug: Tilsotolimod
Drug: Nab-paclitaxel
Drug: ABBV-181

First Posted Date: 2019-12-12

Last Posted Date: 2023-02-27

Lead Sponsor: AbbVie

Target Recruit Count: 30

Registration Number: NCT04196283

Locations: 🇺🇸
The University of Chicago Medical Center /ID# 217196, Chicago, Illinois, United States
🇺🇸
MD Anderson Cancer Center /ID# 214041, Houston, Texas, United States
🇺🇸
Norton Cancer Institute /ID# 216179, Louisville, Kentucky, United States

and more 23 locations

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Upadacitinib

First Posted Date: 2019-12-12

Last Posted Date: 2025-01-09

Lead Sponsor: AbbVie

Target Recruit Count: 475

Registration Number: NCT04195698

Locations: 🇺🇸
Duplicate_First OC Dermatology Research Inc /ID# 218619, Fountain Valley, California, United States
🇺🇸
Duplicate_UC Davis Health /ID# 218582, Sacramento, California, United States
🇺🇸
Duplicate_Michigan Center for Research Company /ID# 218577, Clarkston, Michigan, United States

and more 113 locations

A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation

Completed

Conditions: Hepatitis C Virus (HCV)

First Posted Date: 2019-12-06

Last Posted Date: 2022-06-27

Lead Sponsor: AbbVie

Target Recruit Count: 99

Registration Number: NCT04189627

Locations: 🇷🇺
Irkutsk Regional Center for the Prevention and Control of AIDS and Infections /ID# 222252, Irkutsk, Russian Federation
🇷🇺
Children's Clinical Multidisciplinary Center of the Moscow Region /ID# 226590, Moscow, Russian Federation
🇷🇺
Dagestan State Medical University /ID# 218500, Makhachkala, Dagestan, Respublika, Russian Federation

and more 5 locations

An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Cancer
Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Cofetuzumab Pelidotin

First Posted Date: 2019-12-06

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 65

Registration Number: NCT04189614

Locations: 🇺🇸
The Ohio State University /ID# 211088, Columbus, Ohio, United States
🇺🇸
Stanford University School of Med /ID# 213450, Stanford, California, United States
🇪🇸
Hospital Universitario Fundacion Jimenez Diaz /ID# 215110, Madrid, Spain

and more 23 locations

A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma (MM)
Cancer

Interventions: Drug: ABBV-467

First Posted Date: 2019-11-26

Last Posted Date: 2021-07-26

Lead Sponsor: AbbVie

Target Recruit Count: 8

Registration Number: NCT04178902

Locations: 🇦🇺
Royal Adelaide Hospital /ID# 223354, Adelaide, South Australia, Australia
🇦🇺
Royal Perth Hospital /ID# 225498, Perth, Western Australia, Australia
🇦🇺
Perth Blood Institute Ltd /ID# 226650, Nedlands, Western Australia, Australia

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy